The big news for the week in the biotech space is the huge $12 billionbuyout of Kite Pharma Inc KITE 0.3% by Gilead Sciences, Inc. GILD 0.09%.
Gilead, Kite and other biotech investors are eager to know Wall Street’s take on the big deal and what it means for the market.
Here’s a rundown of what several Wall Street analysts had to say about the deal.
Voices From The Street
Deutsche Bank analyst Andrew Peters says the deal is a sign of a new direction for Gilead. “On this morning’s conference call outlining the rationale for the deal, management strongly emphasized their strategy to use the acquisition as a (sizable) first step in building out a capability in oncology, and that with Kite, they are now a leader in a rapidly emerging field,” Peters wrote. Contrary to most M&A deals, Peters says management isn’t emphasizing the cost-saving, synergistic potential of the deal, but rather the potential it creates for growth driving research and development down the line.
Wells Fargo analyst Jim Birchenough says investors shouldn’t be fooled by Gilead’s relatively low market valuation. “While GILD PE multiple appears depressed relative to near term growth, we believe it is justified based on expected slowing of HCV product revenues and lack of visibility on growth beyond HCV,” he wrote Monday. “Overall, we believe that potential for initial facility loss on CAR-T reimbursement has been underestimated, as has been difficulty in expanding beyond initial centers with lower diagnosis-related group (DRG) exposure.”
Cowen analyst Phil Nadeau said the deal instantly gives Gilead a new innovative product launch on the horizon in Axi-Cel. In addition, Gilead’s entrance into the CAR-T arena will give the company multiple growth avenues and pipeline opportunities. “We are confident both in the potential of Axi-Cel to become a standard therapy in the treatment of aggressive non-Hodgkin’s Lymphoma, as well as Kite’s leadership position in the CAR-T field,” he wrote.
BTIG analyst Dane Leone said there seems to be little obvious risk of regulatory or logistical hang-ups preventing the deal. Kite was an obvious choice in the CAR-T space because of its lack of meaningful joint ventures and ownership ties. “Implicit in the forecast for the KITE deal to be neutral to earnings by Year 3 and accretive thereafter, it would be assumed that Gilead will be able to extract a solid margin over the significant manufacturing costs currently,” Leone wrote.
Ratings And Targets
Analysts have different takes on Gilead stock following news of the deal. Here’s…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
